News Summary
AI biotechnology company Enveda announced on September 23, 2026 that it has completed a $311 million funding round at a $2 billion valuation. The funds will be used to advance more AI-assisted drugs derived from nature into clinical trials. The company is currently testing drug candidates for treating skin diseases and maintaining weight after discontinuing GLP-1 drugs. The round was participated in by both new and existing investors, reflecting capital markets’ latest recognition of AI-driven natural product drug discovery, and providing key support for advancing Enveda’s multiple pipelines.
Background
Natural products have long been an important source of drug R&D, but traditional screening and validation methods are time-consuming and costly. AI biotech companies like Enveda are trying to accelerate the analysis of active molecules from plants and microorganisms through machine learning, thereby improving discovery efficiency. This track has regained attention in recent years after the overall downturn in AI drug development. In particular, as GLP-1 weight-loss drugs have ramped up, weight rebound after stopping treatment has become a clinical pain point, and Enveda’s related pipeline is well positioned. This funding round also shows that investors favor companies with clinical-stage assets over those that remain mere platform stories.
Deep Dive
Liu Gong believes that the biggest signal from Enveda’s fundraising is not the money, but the shift in AI drug development’s narrative from “general platforms” to “specific clinical pain points.” Compared with traditional natural product drug R&D, which often involves ten years of heavy investment, AI compresses the discovery phase, but the risk of failure in the clinical phase is no less. Enveda is currently betting on skin diseases and weight maintenance after stopping GLP-1 treatment. The former is a mature but highly competitive field, while the latter is a blue-ocean gap under the weight-loss wave. The implication is that if relevant trials yield positive data in the next one to two years, the $2 billion valuation will be seen as conservative; otherwise, the market will re-evaluate “AI + natural products” at a discount. The next things to watch are when Enveda’s existing pipeline will read out Phase II or Phase III data, and whether large pharma companies will follow up with partnerships or acquisitions. Liu Gong predicts that this funding heat will continue until the next major clinical failure.
Perspectives
Further Thoughts
- Can natural products combined with AI break through the bottlenecks of traditional drug discovery?
- Weight maintenance after stopping GLP-1 has become a new competitive focus in the weight-loss market.
- At a $2 billion valuation, Enveda’s clinical readouts matter more than the funding number.
Source and Original
This news item is from TechCrunch AI (published on September 23, 2026, 19:31:28). This site provides Chinese summaries and commentary on overseas AI news. The original article’s copyright belongs to its original author.
Aggregating the latest overseas AI news and in-depth perspectives daily. Bookmark this site to never miss an important signal; return to homepage for more.